This includes expanding biomarker profiling beyond PD-L1 and MSI to incorporate additional predictive and prognostic markers—such as tumor mutational burden, tumor-infiltrating lymphocyte density, and circulating tumor DNA for minimal residual disease detection—which could further optimize patient selection and identify those most likely to derive durable benefit. The gene discussed is CD274; the disease is neoplasm.